• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Alucent wins FDA nod for trial of novel drug-device PVD treatment

May 17, 2017 By Sarah Faulkner

Alucent MedicalAlucent Medical said today that it won FDA approval to begin Phase I clinical studies of its Natural Vascular Scaffolding, a novel combination drug-device therapy for the treatment of peripheral vascular disease.

Percutaneous balloon angioplasty, a process that involves drug-coated balloons and metal stents, is the traditional standard of care for peripheral vascular disease. These procedures can cause target lesion revascularization, requiring the need for repeat treatments.

Alucent Medical’s photo-activated drug therapy, NVS, is designed to build natural scaffolding and keep the vessel open, according to the South Dakota-based company.

“The promise of this novel therapy is extraordinary. We believe NVS could deliver quantum advancement in the treatment of peripheral vascular disease with the potential of eliminating vascular stents for this condition,” chairman James Corbett said in prepared remarks.

“NVS has the potential to leap-frog current treatments for peripheral vascular disease,” president & CEO Dr. Myles Greenberg added.

The company’s Phase I program is slated to start this summer.

“We are thrilled that this innovation has reached the point of U.S. clinical trials. We believe it will improve quality of life for many patients, and this ultimately is the Avera mission. We’ve been behind it by supporting and investing in this research, and it is extremely exciting to reach this milestone,” Fred Slunecka, Chief Operating Officer of Avera Health, said.

Alucent Medical is owned by the R&D branch of Avera Health.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Vascular Tagged With: alucentmedical

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS